Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors

被引:0
|
作者
Brittney Shea-Herbert
Krisztina Pongracz
Jerry W Shay
Sergei M Gryaznov
机构
[1] University of Texas Southwestern Medical Center,Department of Cell Biology
[2] Geron Corporation,undefined
来源
Oncogene | 2002年 / 21卷
关键词
telomerase inhibitors; oligonucleotide; phosphoramidates;
D O I
暂无
中图分类号
学科分类号
摘要
Human telomerase is a unique reverse transcriptase that is expressed in multiple cancers, but not in the vast majority of normal cells. The enzyme is responsible for telomere protection and maintenance, and supports the proliferative immortality of cancer cells. Thus, it has been proposed that the specific inhibition of telomerase activity in tumors might have significant and beneficial therapeutic effects. To this goal we have designed, synthesized, and evaluated several oligonucleotide N3′→P5′ phosphoramidates as telomerase inhibitors. These oligonucleotides are complementary to the template region of the RNA domain of telomerase (hTR). The prepared compounds were evaluated in HME50-5E breast epithelial cells, where their effects on telomerase activity were determined using a cell-based telomerase (TRAP) assay at 24 as well as 72 h after exposure to compounds. The oligo-N3′→P5′ phosphoramidate inhibited telomerase activity in cells in the presence of the cellular up-take enhancer (FuGENE6TM) in a dose- and sequence-dependent manner, with IC50 values of approximately 1 nM. Inhibition of telomerase activity by this compound without the lipid carrier was not efficient. However, the isosequential oligonucleotide N3′→P5′ thio-phosphoramidate was able to inhibit telomerase activity with or without lipid carriers at nM, or low-μM concentrations, respectively. This inhibition of telomerase activity in HME50-5E cells by the oligonucleotide thio-phosphoramidates was also sequence specific. Long-term treatment of the cells with 0.5 μM of FuGENE6 formulated 13-mer thio-phosphoramidates, fully complementary to hTR, resulted in gradual telomere shortening, followed by cellular senescence and apoptosis, as would be predicted for a telomerase inhibitor. The mismatched control compound had no effect on cell proliferation. The results suggest that the oligonucleotide N3′→P5′ phosphoramidates, and particularly thio-phosphoramidates, might be further developed as selective anti-telomerase reagents.
引用
收藏
页码:638 / 642
页数:4
相关论文
共 50 条
  • [21] A remarkable stabilization of complexes formed by 2,6-diaminopurine oligonucleotide N3′→P5′ phosphoramidates.
    Matray, T
    Gamsey, S
    Pongracz, K
    Gryaznov, S
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2000, 19 (10-12): : 1553 - 1567
  • [22] Automated synthesis of oligonucleotide (N3'->P5') phosphoramidates using 3'-amino-2',3'-dideoxynucleoside phosphoramidites.
    Rao, TS
    Vu, H
    Akiyama, T
    Hogan, ME
    Ojwang, JO
    Rando, RF
    Revankar, GR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 62 - CARB
  • [23] Oligonucleotide N3′ → P5′ thio-phosphoramidate telomerase template antagonists as potential anticancer agents
    Gryaznov, S
    Asai, A
    Oshima, Y
    Yamamoto, Y
    Pongracz, K
    Pruzan, R
    Wunder, E
    Piatyszek, M
    Li, SH
    Chin, A
    Harley, C
    Akinaga, S
    Yamashita, Y
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2003, 22 (5-8): : 577 - 581
  • [24] Synthesis end properties of RNA analogs -: oligoribonucleotide N3′→P5′ phosphoramidates
    Matray, TJ
    Gryaznov, SM
    NUCLEIC ACIDS RESEARCH, 1999, 27 (20) : 3976 - 3985
  • [25] The effect of telomerase inhibitor oligonucleotide N3′-P5′ phosphoramidate in human multiple myeloma cell lines.
    Akiyama, M
    Hideshima, T
    Hayashi, T
    Tai, TT
    Shammas, M
    Gryaznov, S
    Anderson, KC
    Munshi, NC
    BLOOD, 2002, 100 (11) : 816A - 816A
  • [26] A new approach to oligonucleotide N3′→P5′ phosphoramidate building blocks
    Zielinska, D
    Pongracz, K
    Gryaznov, S
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2005, 24 (5-7): : 1063 - 1067
  • [27] A new approach to oligonucleotide N3′ → P5′ phosphoramidate building blocks
    Zielinska, Daria
    Pongracz, Krisztina
    Gryaznov, Sergei M.
    TETRAHEDRON LETTERS, 2006, 47 (26) : 4495 - 4499
  • [28] Synthetic oligonucleotides as RNA mimetics: 2′-modified RNAs and N3′→P5′ phosphoramidates
    M. Egli
    S. M. Gryaznov*
    Cellular and Molecular Life Sciences CMLS, 2000, 57 : 1440 - 1456
  • [29] Synthetic oligonucleotides as RNA mimetics:: 2′-modified RNAs and N3′→P5′ phosphoramidates
    Egli, M
    Gryaznov, SM
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (10) : 1440 - 1456
  • [30] Antiadhesive effects of GRN163L -: An oligonucleotide N3′→P5′ thio-phosphoramidate targeting telomerase
    Jackson, Shalmica R.
    Zhu, Chun-Hong
    Paulson, Vera
    Watkins, Linda
    Dikmen, Z. Gunnur
    Gryaznov, Sergei M.
    Wright, Woodring L.
    Shay, Jerry W.
    CANCER RESEARCH, 2007, 67 (03) : 1121 - 1129